SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c),
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. 3)*
Alnylam Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
02043Q107
--------------------------
(CUSIP Number)
December 31, 2006
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
________________________________________________________________________________
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Management Limited
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 2,040,000
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH 2,040,000
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,040,000 shares
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.3%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
CO
________________________________________________________________________________
________________________________________________________________________________
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III A L.P.
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 1,850,000
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH 1,850,000
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,850,000 shares
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.8%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
PN
________________________________________________________________________________
________________________________________________________________________________
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III B L.P.
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 1,850,000 shares
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH 1,850,000 shares
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,850,000 shares
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.8%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
PN
________________________________________________________________________________
________________________________________________________________________________
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III C L.P.
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 1,850,000 shares
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH 1,850,000 shares
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,850,000 shares
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.8%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
PN
________________________________________________________________________________
________________________________________________________________________________
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III Executives L.P.
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 1,850,000 shares
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH 1,850,000 shares
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,000,000 shares
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.8%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
PN
________________________________________________________________________________
ITEM 1(a). NAME OF ISSUER: Alnylam Pharmaceuticals, Inc. (the "Issuer")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
300 Third Street, Cambridge, Massachusetts 02142
ITEM 2(a). NAME OF PERSONS FILING: Abingworth Management Limited ("Abingworth
Management"), Abingworth Bioventures III A L.P. ("ABV III A"),
Abingworth Bioventures III B L.P. ("ABV III B"), Abingworth
Bioventures III C L.P. ("ABV III C"), and Abingworth Bioventures III
Executives L.P. ("ABV III Executives" and together with ABV III A,
ABV III B and ABV III C, the "Funds"). The foregoing individuals are
collectively referred to as the "Reporting Persons."
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The
business address for Abingworth Management, ABV III A, ABV III B,
ABV III C and ABV III Executives is c/o Abingworth Management
Limited, Princess House, 38 Jermyn Street, London, England SW1Y 6DN.
ITEM 2(c). CITIZENSHIP: Abingworth Management is a corporation organized under
the laws of England. ABV III A, ABV III B and ABV III C are limited
partnerships organized under the laws of England. ABV III Executives
is a limited partnership organized under the laws of Delaware.
ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, $0.01 par value
per share
ITEM 2(e). CUSIP NUMBER: 02043Q107
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR
13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
Not applicable.
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned: ABV III A is the record owner of
932,962 shares of Common Stock (the "ABV III A Shares") as of
December 31, 2006. ABV III B is the record owner of 566,908
shares of Common Stock (the "ABV III B Shares") as of December
31, 2006. ABV III C is the record owner of 339,593 shares of
Common Stock (the "ABV III C Shares") as of December 31, 2006.
ABV III Executives is the record owner of 14,799 shares of
Common Stock ("ABV III Executives" and together with ABV III
A, ABV III B and ABV III C the "ABV III Funds") as of December
31, 2006. Collectively, the ABV III funds beneficially own
1,850,000 shares of common stock.
The ABV III Funds share a manager, Abingworth Management, and
are affiliated funds, and, on this basis, may be deemed to
beneficially own the shares held by one another. Each of the
ABV III Funds disclaims beneficial ownership of such shares of
Common Stock except for the shares, if any, such ABV III Fund
holds of record. Abingworth Management may be deemed to
beneficially own the shares of Common Stock held of record by
ABV III A, ABV III B, ABV III C, ABV III Executives and
Abingworth Bioequities Master Fund Limited ("ABE"),
representing an aggregate of 2,040,000 shares of Common Stock.
(b) Percent of Class: The ABV III Funds, collectively,
beneficially own 5.8% of the outstanding Common Stock of the
Issuer. Abingworth Management may be deemed to beneficially
own the shares of Common Stock held of record by ABV III A,
ABV III B, ABV III C, ABV III Executives and ABE, representing
an aggregate of 6.3% of the outstanding Common Stock of the
Issuer.
The foregoing percentages are calculated based on the
32,176,921 shares of Common Stock reported to be outstanding
as of September 30, 2006 in the Issuer's Form 10-Q filed with
the Securities Exchange Commission on November 9, 2006.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: see line 5 of
cover sheets.
(ii) shared power to vote or to direct the vote: see line 6
of cover sheets.
(iii) sole power to dispose or to direct the disposition:
see line 7 of cover sheets.
(iv) shared power to dispose or to direct the disposition:
see line 8 of cover sheets.
Each Reporting Person disclaims beneficial ownership of such shares
of Common Stock except for the shares, if any, such Reporting Person
holds of record.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
ITEM 10. CERTIFICATION.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in
any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: February 12, 2007
ABINGWORTH MANAGEMENT LIMITED
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III A L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III B L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III C L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III EXECUTIVES L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
EXHIBIT 1
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of Common Stock of Alnylam Pharmaceuticals, Inc.
EXECUTED as a sealed instrument this 12th day of February, 2007.
ABINGWORTH MANAGEMENT LIMITED
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III A L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III B L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III C L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director
ABINGWORTH BIOVENTURES III EXECUTIVES L.P.
By: Abingworth Management Limited, its Manager
By: /s/ DAVID LEATHERS
-----------------------------
Name: David Leathers
Title: Executive Director